Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/16 23:43:54」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 収縮能障害による心不全におけるβブロッカーの使用 use of beta blockers in heart failure due to systolic dysfunction
- 2. 収縮能障害による心不全の治療の概要 overview of the therapy of heart failure due to systolic dysfunction
- 3. 収縮能障害による心不全におけるβブロッカー使用の理論的根拠および臨床試験 rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction
English Journal
- Cardiovascular pharmacogenomics: expectations and practical benefits.
- Turner RM, Pirmohamed M.Author information 1] The Wolfson Centre for Personalised Medicine, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK [2] Clinical Pharmacology, The Royal Liverpool University Hospital, Liverpool, UK.AbstractCardiovascular disease is a leading cause of morbidity and mortality worldwide. Pharmacogenomics is the study of genetic determinants of interindividual variation in drug response and aims to facilitate personalized medicine, through genotype-informed drug and dose selection, to maximize drug efficacy and/or minimize adverse drug reactions. Despite high expectations, no cardiovascular pharmacogenomic association is currently in widespread clinical practice; evidential, logistical, financial, and knowledge implementation barriers exist. Nevertheless, VKORC1, CYP2C9, and CYP4F2 variants have been associated with warfarin dose requirements, and CYP2C19 variants have been associated with perturbed antiplatelet response to clopidogrel. However, at present, controversy exists over the clinical utility of these genetic associations. There is an increased risk of simvastatin-induced muscle toxicity in SLCO1B1*5 carriers, ADRB1 and ADRA2C polymorphisms are associated with differential response to bucindolol, and rare congenital arrhythmia gene variants have been identified in drug-induced torsade de pointes. Practical benefits are still anticipated, but much work remains.
- Clinical pharmacology and therapeutics.Clin Pharmacol Ther.2014 Mar;95(3):281-93. doi: 10.1038/clpt.2013.234. Epub 2013 Dec 9.
- Cardiovascular disease is a leading cause of morbidity and mortality worldwide. Pharmacogenomics is the study of genetic determinants of interindividual variation in drug response and aims to facilitate personalized medicine, through genotype-informed drug and dose selection, to maximize drug effica
- PMID 24322971
- β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction.
- Lymperopoulos A1, Negussie S, Walklett K.
- Pharmacogenomics.Pharmacogenomics.2013 Oct;14(13):1545-9. doi: 10.2217/pgs.13.137.
- PMID 24088125
- Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta1389 Arg/Gly Adrenergic Receptor Polymorphism.
- Aleong RG1, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR.Author information 1Section of Cardiac Electrophysiology, University of Colorado Denver, Denver, Colorado.AbstractOBJECTIVES: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF) patients enrolled in the BEST (Beta-Blocker Evaluation of Survival Trial).
- JACC. Heart failure.JACC Heart Fail.2013 Aug 1;1(4):338-344.
- OBJECTIVES: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF) patients enrolled in the BEST (Beta-Blocker Evaluation of Survival Tr
- PMID 24159564
Japanese Journal
- Partial agonist activity of bucindolol is dependent on the activation state of the human β_1-adrenergic receptor
- MAACK C
- Circulation 108, 348-353, 2003
- NAID 30022668793
- Comparison of the beta blocker bucindolol in younger vs older patients with heart failure
- ARANDA JM
- Am J Cardiol 89, 1322-1326, 2002
- NAID 30004361646
- Bucindolol exerts agonistic activity on the propranolol-insensitive state of β_1-adrenoceptors in human myocardium
- BUNDKIRCHEN A
- J Pharmacol Exp Ther 300, 794-801, 2002
- NAID 30003044737
Related Links
- Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity. It was under review by the FDA in the United States for the treatment of heart failure in 2009 .
Related Pictures
★リンクテーブル★
| リンク元 | 「ブシンドロール」 |
| 拡張検索 | 「bucindolol hydrochloride」 |